Provided herein are, inter alia, method and compositions for treating vascular Ehlers-Danlos syndrome and related syndromes. Also included herein are kits for treating vascular Ehlers-Danlos syndrome and related syndromes.

This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

ABSTRACT: A formulation of Collagen peptides with enzyme inhibitors and hyaluronic acid would increase the levels of collagen and elastin and hyaluronic acid for a long period of time, and would decrease the rate of aging, and age-related changes in the skin and other organs. During aging, the levels of these molecules decrease because of enhanced activities of their respective enzymes. Current approach has utilized collagen peptides alone to increase the levels of collagen and elastin in order to maintain healthy skin. In the absence of inhibitors of enzymes collagenase and elastase, and hyaluronic acid, the levels of collagen peptides, elastin, and hyaluronic acid would decrease. Consequently, the beneficial effects of collagen peptides alone would be reduced within a short period of time.

A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.

Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

An alginate-based nutritional product (“AP”) comprising a composition and digestive aid. AP includes alginate as a demulcent (protective), raft-forming, stabilizing agent, polylysine, dextrose and grapefruit seed extract preservatives. The pharmaceutical composition is intended for the relief or prophylaxis of acid reflux and other forms of indigestion in mammals. In some embodiments, dextrose and polylysine are combined to form a preservative for the alginate-based nutritional supplement. In other embodiments, dextrose (or other common sugars known in the art), grapefruit seed extract, and polylysine are combined to form a preservative for the alginate-based nutritional supplement.